Xeris Biopharma Target of Unusually High Options Trading (NASDAQ:XERS)

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) saw some unusual options trading on Tuesday. Stock traders acquired 9,035 call options on the stock. This is an increase of 1,543% compared to the typical volume of 550 call options.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.80.

Xeris Biopharma Stock Up 6.0%

XERS stock traded up $0.51 during mid-day trading on Tuesday, reaching $8.88. The company had a trading volume of 1,668,490 shares, compared to its average volume of 1,899,138. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of 147.92 and a beta of 0.62. The firm has a fifty day simple moving average of $6.65 and a 200 day simple moving average of $6.64. Xeris Biopharma has a fifty-two week low of $4.66 and a fifty-two week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The business had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Analysts forecast that Xeris Biopharma will post 0.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Xeris Biopharma news, Director Marla Persky sold 15,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $5.90, for a total transaction of $91,450.00. Following the sale, the director directly owned 126,500 shares in the company, valued at $746,350. This represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dawn Halkuff sold 20,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $121,800.00. Following the sale, the director directly owned 95,000 shares in the company, valued at $578,550. This represents a 17.39% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 206,500 shares of company stock worth $1,463,405 over the last 90 days. 4.35% of the stock is owned by insiders.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently modified their holdings of XERS. Royal Bank of Canada raised its holdings in Xeris Biopharma by 1,411.2% during the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP purchased a new position in shares of Xeris Biopharma in the 1st quarter valued at $170,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.